Antares Pharma (ATRS) Peer Comparison

$5.59

$0.00 (0.00%)

As on 24-May-2022 09:30EDT

Market cap

$955 Mln

Revenue (TTM)

$183 Mln

P/E Ratio

24.1

P/B Ratio

5.4

Div. Yield

0 %

Edit

	Antares Pharma (ATRS)	Intricon (IIN)
Market cap ($ Mln)	955	225
Revenue ($ Mln)	183	127
Net Profit ($ Mln)	42.46	-1.48
Net Margin (%)	23.16	-1.17
RoE (%)	26.82	-2.56
Price to Earnings	24.09	--
Price-To-Book	5.43	2.41

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Antares Pharma (ATRS)	Intricon (IIN)
Operating Revenue	183.46	126.50
Cost of Revenue	70.60	94.45
Gross Profit	115.70	31.39
Operating Expenses	112.69	31.81
Operating Profit (EBIT)	57.72	-0.79
Other Income	-0.15	-0.47
Profit before Tax	54.75	-1.27
Provision for Tax	12.29	0.06
Profit after Tax (Net Income)	42.46	-1.48
Minority Interest	0.00	0.15
Consolidated Profit	40.18	-1.48

Liabilities ($ Mln)

	Antares Pharma (ATRS)	Intricon (IIN)
Shareholder's Funds	175.77	93.61
Minority Interest	0.00	0.15
Non-Current Liabilities	24.16	8.80
Current Liabilities	55.73	23.95
Total Liabilities	257.51	122.46

Assets ($ Mln)

	Antares Pharma (ATRS)	Intricon (IIN)
Non-Current Assets	84.07	49.90
Current Assets	171.59	76.62
Total Assets	257.51	122.36
Total Debt*	25.49	6.36
Net Current Assets	115.86	52.67

Cashflow ($ Mln)

	Antares Pharma (ATRS)	Intricon (IIN)
Cash From Operating Activities	36.62	0.44
Cash Flow from Investing Activities	-3.85	-2.22
Cash from Financing Activities	-19.99	-1.15
Net Cash Inflow / Outflow	12.78	-2.94

Ratios

Profitability Ratios

	Antares Pharma (ATRS)	Intricon (IIN)
ROCE (%)	25.65	-0.11
ROE (%)	26.82	-2.56
ROA (%)	14.11	-0.99
EBIT Margin (%)	30.97	-1.12
Net Margin (%)	23.16	-1.17
Cash Profit Margin (%)	0.00	0.00

Growth Ratios

	Antares Pharma (ATRS)	Intricon (IIN)
Revenue Growth (%)	15.67	11.91
EBIT Growth (%)	179.19	-569.54
Net Profit Growth (%)	-31.90	-973.96
EPS Growth (%)	-33.85	-1,647.77
Book Value Growth (%)	43.35	12.69

Valuation Ratios

	Antares Pharma (ATRS)	Intricon (IIN)
Price / Earnings	13.50	-1,372.92
Price / Book Value	3.55	1.55
Dividend Yield (%)	--	--
EV/EBITDA	8.79	22.49
Market Cap ($ Cr)	--	--

Solvency Ratios

	Antares Pharma (ATRS)	Intricon (IIN)
Debt to Equity	0.10	0.00
Short term debt to equity ratio	0.01	0.02
Current Ratio	3.08	3.20
Quick Ratio	2.87	2.01
Interest Coverage	20.39	-27.29

Operating Efficiency Ratios

	Antares Pharma (ATRS)	Intricon (IIN)
Debtors to sales (%)	50.85	18.72
Asset Turnover	0.61	0.85
Receivable days	132.39	56.79
Inventory Days	79.60	85.59
Payable days	88.93	35.17
Cash Conversion Cycle	123.05	107.21

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly